-
公开(公告)号：US20190202798A1
公开(公告)日：2019-07-04
申请号：US16296319
申请日：2019-03-08
Applicant: Pfizer Inc.
Inventor： John Robert Springer , Balekudru Devadas , Danny James Garland , Margaret Lanahan Grapperhaus , Seungil Han , Susan Landis Hockerman , Robert Owen Hughes , Eddine Saiah , Mark Edward Schnute , Shaun Raj Selness , Daniel Patrick Walker , Zhao-Kui Wan , Li Xing , Christoph Wolfgang Zapf , Michelle Ann Schmidt
IPC: C07D401/04
Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases cases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I)
-
公开(公告)号：US11629172B2
公开(公告)日：2023-04-18
申请号：US16721229
申请日：2019-12-19
Applicant: Pfizer Inc.
Inventor： Philip Ralph Dormitzer , Ye Che , Xiaoyuan Sherry Chi , Seungil Han , Kyle Paul Heim , Thomas Richard Jones , Yuhang Liu , Xiayang Qiu , Xinzhen Yang , Xiaojie Yao , Matthew Curtis Griffor , Jennifer Anne Nicki
IPC: C07K14/005 , A61K39/00
Abstract: The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least one introduced amino acid mutation relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.
-
公开(公告)号：US20200247853A1
公开(公告)日：2020-08-06
申请号：US16721229
申请日：2019-12-19
Applicant: Pfizer Inc.
Inventor： Philip Ralph Dormitzer , Ye Che , Xiaoyuan Sherry Chi , Seungil Han , Kyle Paul Heim , Thomas Richard Jones , Yuhang Liu , Xiayang Qiu , Xinzhen Yang , Xiaojie Yao , Matthew Curtis Griffor , Jennifer Anne Nicki
IPC: C07K14/005
Abstract: The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least one introduced amino acid mutation relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.
-
公开(公告)号：US09458168B2
公开(公告)日：2016-10-04
申请号：US14678114
申请日：2015-04-03
Applicant: Pfizer Inc.
Inventor： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Richard Vargas , Michael Dennis Lowe , Akshay Patny
IPC: C07D207/26 , C07D401/12 , A61K31/44 , C07D491/056 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D215/48 , C07D403/12 , C07D405/12 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D401/14 , C07D405/14 , C07D217/02 , C07D217/22 , C07D217/24 , C07C69/94 , C07D239/86 , C07D239/88 , C07D263/24 , C07D207/273 , C07D498/04 , C07D209/52 , C07F7/18
CPC classification number: C07D491/056 , A61K31/40 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C69/94 , C07D207/08 , C07D207/26 , C07D207/267 , C07D207/273 , C07D209/52 , C07D215/48 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D498/04 , C07F7/1804
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号：US20150291554A1
公开(公告)日：2015-10-15
申请号：US14439478
申请日：2013-11-01
Applicant: PFIZER INC.
Inventor： John Robert Springer , Balekudru Devadas , Danny James Garland , Margaret Lanahan Grapperhaus , Seungil Han , Susan Landis Hockerman , Robert Owen Hughes , Eddine Saiah , Mark Edward Schnute , Shaun Raj Selness , Daniel Patrick Walker , Zhao-Kui Wan , Li Xing , Christoph Wolfgang Zapf , Michelle Ann Schmidt
IPC: C07D401/04
CPC classification number: C07D401/04
Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Abstract translation: 本文公开的是与布鲁顿酪氨酸激酶（BTK）形成共价键的化合物。 公开了制备化合物的方法。 还公开了包含化合物的药物组合物。 公开了使用BTK抑制剂的方法，单独或与其它治疗剂组合用于治疗自身免疫性疾病或病症，异种免疫性疾病或病症，癌症，包括淋巴瘤和炎性疾病或病症。
-
Patent Agency Ranking
公开(公告)号：US20190270751A1
公开(公告)日：2019-09-05
申请号：US16411679
申请日：2019-05-14
Applicant: Pfizer Inc.
Inventor： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Betsy Susan Pierce , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , David Randolph Anderson , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Horng-Chih Huang , Richard Vargas , Michael Dennis Lowe , Akshay Patny
IPC: C07D491/056 , C07F7/18 , A61K31/4015 , C07D207/267 , C07D207/08 , C07D209/52 , C07D498/04 , C07D207/273 , C07D263/24 , C07D239/88 , C07D239/86 , C07C69/94 , C07D217/24 , C07D217/22 , C07D217/02 , C07D405/14 , C07D401/14 , C07D487/04 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D207/26 , C07D215/48 , C07D401/12 , C07D403/12 , C07D405/12 , C07D407/14 , C07D413/12 , C07D417/12 , A61K31/40
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号：US10316018B2
公开(公告)日：2019-06-11
申请号：US16206166
申请日：2018-11-30
Applicant: PFIZER INC.
Inventor： Katherine Lin Lee , Christophe Philippe Allais , Christoph Martin Dehnhardt , Lori Krim Gavrin , Seungil Han , David Hepworth , Arthur Lee , Frank Eldridge Lovering , John Paul Mathias , Dafydd Rhys Owen , Nikolaos Papaioannou , Eddine Saiah , Joseph Walter Strohbach , John David Trzupek , Stephen Wayne Wright , Christoph Wolfgang Zapf
IPC: A61K31/4375 , A61K31/4709 , A61K31/4725 , A61K31/4745 , A61K31/4015 , A61K45/06 , C07D401/12 , C07D413/04 , C07D207/273 , C07D491/18 , C07D471/04 , C07D413/14 , C07D401/14
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号：US10174000B2
公开(公告)日：2019-01-08
申请号：US15754650
申请日：2016-08-16
Applicant: PFIZER INC.
Inventor： Katherine Lin Lee , Christophe Philippe Allais , Christoph Martin Dehnhardt , Lori Krim Gavrin , Seungil Han , David Hepworth , Arthur Lee , Frank Eldridge Lovering , John Paul Mathias , Dafydd Rhys Owen , Nikolaos Papaioannou , Eddine Saiah , Joseph Walter Strohbach , John David Trzupek , Stephen Wayne Wright , Christoph Wolfgang Zapf
IPC: C07D207/273 , C07D401/12 , C07D401/14 , C07D413/04 , C07D413/14 , C07D471/04 , C07D491/18 , A61K31/4015 , A61K31/4375 , A61K31/4709 , A61K31/4725 , A61K31/4745 , A61K45/06
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号：US20150284405A1
公开(公告)日：2015-10-08
申请号：US14678114
申请日：2015-04-03
Applicant: Pfizer Inc.
Inventor： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Betsy Susan Pierce , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , David Randolph Anderson , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Horng-Chih Huang , Richard Vargas , Michael Dennis Lowe , Akshay Patny
IPC: C07D491/056 , A61K31/4709 , A61K45/06 , C07D405/12 , C07D215/48 , A61K31/47 , A61K31/4725 , C07D417/12 , A61K31/541 , C07D413/12 , A61K31/5377 , C07D207/26 , A61K31/4015 , C07D407/14 , C07D487/04 , C07D403/12 , A61K31/517 , C07D401/12
CPC classification number: C07D491/056 , A61K31/40 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C69/94 , C07D207/08 , C07D207/26 , C07D207/267 , C07D207/273 , C07D209/52 , C07D215/48 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D498/04 , C07F7/1804
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
Abstract translation: 公开了化合物的化合物，互变异构体和药学上可接受的盐，其中化合物具有如说明书中定义的式Ia结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。
-
公开(公告)号：US10815213B2
公开(公告)日：2020-10-27
申请号：US16296319
申请日：2019-03-08
Applicant: Pfizer Inc.
Inventor： John Robert Springer , Balekudru Devadas , Danny James Garland , Margaret Lanahan Grapperhaus , Seungil Han , Susan Landis Hockerman , Robert Owen Hughes , Eddine Saiah , Mark Edward Schnute , Shaun Raj Selness , Daniel Patrick Walker , Zhao-Kui Wan , Li Xing , Christoph Wolfgang Zapf , Michelle Ann Schmidt
IPC: C07D401/04 , C07D401/14 , A61K31/4155 , A61K31/454 , A61P29/00 , A61P35/00
Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I)
-
-
-
-
-
-
-
-
-
Search Results
23
records
(took 0.03 seconds)
